NCT06546488 · RECRUITING
Cognitive Assessment Tools for Huntington's Disease.
This study is testing whether two cognitive screening tools, the Coding Test and the SAGE (Self-Administered Gerocognitive Examination), work well for people with Huntington's Disease. Both tools have been used in Alzheimer's and Parkinson's research but have not been studied much in HD. The phase is unspecified, which typically means this is observational research rather than a drug trial.
You may qualify if
- Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
- Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
- A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
- Vision and hearing sufficient for compliance with tests.
- On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
You're excluded if
- Age of symptom onset less than 19 years old or greater than 60 years old.
- Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
- Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
- Subjects who are pregnant or breast feeding
- Subjects with a history of a learning disability.
- Subjects who are unable to provide consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-02